Get the Stockscreener App
8.10
0.74%
-0.06
After Hours:
7.85
-0.25
-3.09%
Wave Life Sciences Ltd stock is traded at $8.10, with a volume of 1.56M.
It is down -0.74% in the last 24 hours and up +24.62% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$8.16
Open:
$8.03
24h Volume:
1.56M
Relative Volume:
1.09
Market Cap:
$1.26B
Revenue:
$53.61M
Net Income/Loss:
$-142.52M
P/E Ratio:
-7.2973
EPS:
-1.11
Net Cash Flow:
$-141.83M
1W Performance:
-3.46%
1M Performance:
+24.62%
6M Performance:
-29.99%
1Y Performance:
+22.54%
1-Day Range:
$7.99
$8.40
1-Week Range:
$7.75
$8.88
52-Week Range:
$5.04
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
8.10 | 1.27B | 53.61M | -142.52M | -141.83M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
Is it the right time to buy Wave Life Sciences Ltd. stockStock Strategy Recommendation From AI Tools - jammulinksnews.com
Wave (WVE) Q2 Revenue Drops 56% - AOL.com
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 26% Share Price Surge Not Quite Adding Up - simplywall.st
What catalysts could drive Wave Life Sciences Ltd. stock higher in 2025Expert Picks Tips For Beginners - jammulinksnews.com
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
WAVE Life Sciences Ltd (WVE) Q2 2025 Earnings Call Highlights: Progress in RNA Editing Amid ... - Yahoo.co
Wave (WVE) Q2 Revenue Drops 56% - The Motley Fool
Wave Life Sciences Advances RNA Medicine Pipeline - TipRanks
WAVE Life Sciences Q2 2025 Earnings Call Transcript - MarketBeat
Wave Life Sciences 2025 Q2 Earnings Revenue Drops 56%, Net Loss Widens - AInvest
Wave Life Sciences: Q2 Earnings Snapshot - Greenwich Time
Top Risks to Consider Before Buying Wave Life Sciences Ltd. StockOversold Recovery Opportunity Stocks Attract Buyers - metal.it
WaveLife Flat on Q2 Results - Baystreet.ca
WAVE Life Sciences Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Wave Life Sciences Ltd earnings missed by $0.04, revenue fell short of estimates - Investing.com Nigeria
Wave Life Sciences Ltd. SEC 10-Q Report - TradingView
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - TradingView
What makes Wave Life Sciences Ltd. stock price move sharplyLow Risk Picks for Daily Trading Released - metal.it
Wave Life Sciences Q2 2025 Earnings Preview - MSN
What is the risk reward ratio of investing in Wave Life Sciences Ltd. stockSuperior risk-adjusted returns - jammulinksnews.com
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
What are the latest earnings results for Wave Life Sciences Ltd.Maximize your returns with expert insights - jammulinksnews.com
Oppenheimer initiates Wave Life Sciences stock with Outperform rating - Investing.com Australia
Oppenheimer initiates Wave Life Sciences stock with Outperform rating By Investing.com - Investing.com South Africa
Wave Life Sciences WVE Q2 2025 Earnings Preview Upside Potential on Clinical Progress and Operational Adjustments - AInvest
How many analysts rate Wave Life Sciences Ltd. as a “Buy”Track top-performing stocks in real-time - jammulinksnews.com
When is Wave Life Sciences Ltd. stock expected to show significant growthCapitalize on strong market momentum - jammulinksnews.com
What is the dividend policy of Wave Life Sciences Ltd. stockAchieve breakthrough profits with expert advice - jammulinksnews.com
What are analysts’ price targets for Wave Life Sciences Ltd. in the next 12 monthsFree Investment Portfolio Suggestions - jammulinksnews.com
Wave Life Sciences Ltd. Stock Analysis and ForecastSuperior profit margins - PrintWeekIndia
What risks could impact Wave Life Sciences Ltd. stock performanceConsistently exceptional gains - jammulinksnews.com
What analysts say about Wave Life Sciences Ltd. stockExplosive trading growth - PrintWeekIndia
Is Wave Life Sciences Ltd. a good long term investmentLightning-fast growth - Autocar Professional
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 - GlobeNewswire
Wave Life Sciences to Host Webcast for Q2 2025 Financial Results and Business Updates - Quiver Quantitative
Wave Life Sciences RNA Medicine Pioneer Announces Q2 2025 Earnings DateKey Updates Expected - Stock Titan
What drives Wave Life Sciences Ltd. stock priceFree Stock Selection - jammulinksnews.com
Why Wave Life Sciences Ltd. stock attracts strong analyst attentionFree Join Group - Newser
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):